January 16, 2023
2 min watch
Save
VIDEO: Wet AMD therapy could be ‘transformative’ for VEGF-mediated diseases
Issue: March 10, 2023
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
KOLOA, Hawaii — In this Healio Video Perspective from Retina 2023, Jay S. Duker, MD, discusses EyePoint Pharmaceuticals’ EYP-1901, a tyrosine kinase inhibitor for patients with wet AMD.
“We believe EYP-1901 could be transformative in the treatment of VEGF-mediated diseases,” he said. “We think the inserts could last between 6 months and 9 months in the eye, giving the majority of wet AMD patients good control as a maintenance therapy.”
Published by:
Sources/Disclosures
Collapse
Source:
Healio Interviews
Disclosures:
Duker is president and CEO of EyePoint Pharmaceuticals.
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.